SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

-	-
OMB Number:	3235-0287
Estimated average b	urden
hours per response:	0.5

1. Name and Address of Reporting Person* 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Beetham Thomas W. 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) (Last) (First) (Middle) C/O MAGENTA THERAPEUTICS, INC. 3. Date of Earliest Transaction (Month/Day/Year) 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) IOO TECHNOLOGY SQUARE 3. Date of Earliest Transaction (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) (Street) CAMBRIDGE MA 02139 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) (City) (State) (Zip) (Zip) 5. State) Form filed by One Reporting Person	Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 193	
In Name and Address of Reporting Person Magenta Therapeutics, Inc. [MGTA] (Check all applicable) Check all applicable) Imagenta Therapeutics, Inc. Magenta Therapeutics, Inc. [MGTA] Director 10% Owner (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) Officer (give title Other (specify below) 09/16/2021 3. Date of Check all applicable) See Remarks See Remarks (Street) CAMBRIDGE MA 02139 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person	· ·		
(Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) See Remarks C/O MAGENTA THERAPEUTICS, INC. 09/16/2021 See Remarks 100 TECHNOLOGY SQUARE 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) (Street) CAMBRIDGE MA 02139 5. Value of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by One Reporting Person Form filed by More than One Reporting Person	1 0	3 ,	Check all applicable) Director
(Street) CAMBRIDGE MA 02139 	C/O MAGENTA THERAPEUTICS, INC.		, , ,
	CAMBRIDGE MA 02139	4. If Amendment, Date of Original Filed (Month/Day/Year)	Line) X Form filed by One Reporting Person Form filed by More than One Reporting

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)	ction	4. Securities Disposed Of 5)			5. Amount of Securities Beneficially Owned Following		7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock	09/16/2021		S ⁽¹⁾		6,103	D	\$6.73 ⁽²⁾	13,897	D	

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number 6 of E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. This transaction represents shares sold solely to pay taxes due upon the vesting of restricted stock units, as disclosed by the reporting person on the Form 4 filed on September 16, 2021.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$6.60 to \$6.87, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

Chief Legal Officer and Secretary

<u>/s/ Cindy Driscoll, Attorney-</u> in-Fact for Thomas W. 09/20/2021 Beetham

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).